Complex stromal and tumour cell interactions have previously been shown to be potent drivers of resistance during MAPK inhibitor therapies through the secretion of different growth factors such as TNFα, HGF and others (Hirata et al., 2015; Lito et al., 2012; Smith et al., 2014; Straussman et al., 2012). Here, HGF is linked to neoplasm.